Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

 (NOVN)

54
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
06/13/2013 06/14/2013 06/17/2013 06/18/2013 06/19/2013 Date
66.95(c) 66.9(c) 67.75(c) 67.15(c) 67.15 Last
4 166 604 3 691 949 3 307 565 3 973 775 4 137 439 Volume
-0.30% -0.07% +1.27% -0.89% 0.00% Change
More quotes
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (55.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Surperformance© rating of Novartis AG
Trading Rating : Investor Rating :
More about the company
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 57 421 M
EBIT 2013 13 400 M
Net income 2013 9 666 M
Debt 2013 6 734 M
Yield 2013 3,39%
Sales 2014 59 362 M
EBIT 2014 14 530 M
Net income 2014 11 153 M
Debt 2014 1 869 M
Yield 2014 3,60%
PER 2013 17,21
PER 2014 15,69
EV / Sales 2013 3,55x
EV / Sales 2014 3,35x
Capitalization 196 987 M
More Financials
Latest news on NOVARTIS AG
5h ago EU fines Lundbeck and others 146 mln euros for blocking rival drugs
6h ago EU fines Lundbeck and others 146 million euros for blocking rival drugs
9h ago EU fines Lundbeck, 8 others 146 million euros for blocking cheaper drugs
2d ago NOVARTIS AG: Three Scientists to Receive Prestigious Novartis Prizes for Immuno..
3d ago NOVARTIS AG: Novartis drug Jakavi® improved overall survival of myelofibrosis p..
5d agoDJMedivir recruits New Head of Commercial Operations
06/11DJQuestcor Acquires Rights to Synacthen From Novartis
06/10 AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion
06/10 AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion
06/06DJAlliance Pharma Buys All Existing Rights to Syntometrine for $11.5 Million
06/05 NOVARTIS AG: New data at ENS show Novartis drug Gilenya benefited patients by i..
06/03 NOVARTIS AG: Novartis Breakthrough Therapy LDK378 shows a marked clinical respo..
More news
Forum NOVARTIS AG
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
EPS Revisions
Novartis AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.